Published in Lung Cancer on July 30, 2007
Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res (2009) 1.73
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res (2010) 1.22
Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer (2007) 1.14
Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis (2008) 1.14
Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM. BMC Cancer (2009) 1.06
Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PLoS One (2012) 1.03
Epigenomics in environmental health. Front Genet (2011) 1.02
Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis. Breast Cancer Res Treat (2008) 1.00
SYK allelic loss and the role of Syk-regulated genes in breast cancer survival. PLoS One (2014) 0.86
Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma. J Adv Res (2013) 0.82
Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. Cancers (Basel) (2010) 0.82
Cytosine 5-Hydroxymethylation of the LZTS1 Gene Is Reduced in Breast Cancer. Transl Oncol (2013) 0.82
Expression of metallothionein and Nrf2 pathway genes in lung cancer and cancer-surrounding tissues. World J Surg Oncol (2013) 0.79
Regulation of MUC5B Expression in Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol (2017) 0.78
Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models. Oncotarget (2016) 0.75
Hypomethylation reduced the aggressive potential of human malignant mesothelioma cells. Cancer Gene Ther (2016) 0.75
Simplified mammalian DNA isolation procedure. Nucleic Acids Res (1991) 12.56
Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (2001) 10.37
The power and the promise of DNA methylation markers. Nat Rev Cancer (2003) 9.32
MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res (2000) 9.30
A gene hypermethylation profile of human cancer. Cancer Res (2001) 8.93
Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res (2005) 6.49
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med (2005) 4.11
Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res (2002) 3.90
Cancer epigenetics. Hum Mol Genet (2005) 3.63
Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer (2004) 3.10
Health and environmental consequences of the world trade center disaster. Environ Health Perspect (2004) 2.87
Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell (2004) 2.73
Changing trends in US mesothelioma incidence. Occup Environ Med (2004) 2.56
CpG-island methylation in aging and cancer. Curr Top Microbiol Immunol (2000) 2.54
Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol (2005) 2.34
Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene (2003) 1.59
Cellular and molecular parameters of mesothelioma. J Cell Biochem (2006) 1.57
Asbestos and mesothelioma: worldwide trends. Lung Cancer (2005) 1.57
Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene (2004) 1.52
Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res (2001) 1.51
Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res (2004) 1.51
Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology (2005) 1.45
Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol (1999) 1.38
Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer (2004) 1.32
Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer (2003) 1.25
Retracted Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene (2005) 1.25
Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res (2006) 1.23
Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer (2005) 1.21
Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res (2001) 1.21
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res (2006) 1.19
MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.18
DNA methylation analysis by MethyLight technology. Methods (2001) 1.15
Gene expression profiling of malignant mesothelioma. Clin Cancer Res (2003) 1.10
Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis (2002) 1.09
The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis Markers (2007) 1.09
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol (1993) 1.08
Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun (2006) 1.08
Changing trends in US mesothelioma incidence. Occup Environ Med (2005) 1.07
Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer (2005) 1.06
Soluble mesothelin-related protein--a blood test for mesothelioma. Lung Cancer (2005) 1.06
Microarray-based survey of CpG islands identifies concurrent hyper- and hypomethylation patterns in tissues derived from patients with breast cancer. Genes Chromosomes Cancer (2006) 1.05
Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer (2005) 1.03
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer (2006) 1.03
Epigenetic regulation of metallothionein-i gene expression: differential regulation of methylated and unmethylated promoters by DNA methyltransferases and methyl CpG binding proteins. J Cell Biochem (2006) 0.96
Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep (2004) 0.95
Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer (2002) 0.93
Suppression of metallothionein-I/II expression and its probable molecular mechanisms. Environ Health Perspect (2002) 0.91
Mesothelioma with clear cell features: an ultrastructural and immunohistochemical study of 20 cases. Hum Pathol (2005) 0.90
Mesothelioma: new concepts in diagnosis and management. Curr Opin Pulm Med (2000) 0.87
Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma. Cancer (1999) 0.85
Predictive and prognostic factors in malignant pleural mesothelioma. Curr Opin Oncol (2003) 0.82
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res (2005) 6.49
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet (2011) 5.70
Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet (2011) 4.26
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med (2005) 4.11
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol (2011) 3.97
Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol (2002) 3.79
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71
Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol (2002) 3.61
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One (2007) 3.30
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg (2008) 2.93
Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns. Hum Mol Genet (2009) 2.85
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol (2007) 2.83
Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res (2008) 2.81
Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol (2012) 2.56
Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol (2006) 2.55
CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res (2012) 2.50
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst (2010) 2.38
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol (2009) 2.26
BAP1 and cancer. Nat Rev Cancer (2013) 2.23
Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst (2003) 2.22
Low-level processing of Illumina Infinium DNA Methylation BeadArrays. Nucleic Acids Res (2013) 2.19
Recommendations for the design and analysis of epigenome-wide association studies. Nat Methods (2013) 2.19
TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A (2006) 2.14
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res (2012) 2.10
Breast cancer: do specialists make a difference? Ann Surg Oncol (2003) 2.09
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) (2008) 2.04
DNA methylation as a biomarker for cardiovascular disease risk. PLoS One (2010) 2.04
Bis-SNP: combined DNA methylation and SNP calling for Bisulfite-seq data. Genome Biol (2012) 2.02
Variants on 9p24 and 8q24 are associated with risk of colorectal cancer: results from the Colon Cancer Family Registry. Cancer Res (2007) 2.02
Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol (2006) 2.01
Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1. Coactivator-associated arginine methyltransferase. J Biol Chem (2002) 2.01
Null association between histology of first and second primary malignancies in men with bilateral testicular germ cell tumors. Am J Epidemiol (2013) 2.00
CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol (2004) 2.00
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol (2004) 2.00
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res (2006) 1.96
Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog (2010) 1.94
A comparison of cluster analysis methods using DNA methylation data. Bioinformatics (2004) 1.94
Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res (2010) 1.94
High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol (2015) 1.93
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol (2006) 1.92
Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One (2009) 1.90
DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene (2002) 1.89
The development and deployment of Common Data Elements for tissue banks for translational research in cancer - an emerging standard based approach for the Mesothelioma Virtual Tissue Bank. BMC Cancer (2008) 1.88
The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology (2010) 1.88
A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics (2004) 1.88
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.85
Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A (2011) 1.80
Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol (2009) 1.79
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med (2012) 1.76
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol (2007) 1.74
Sublobar resection: a movement from the Lung Cancer Study Group. J Thorac Oncol (2010) 1.74
Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol (2007) 1.74
Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. Cancer Res (2002) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst (2002) 1.72
Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev (2009) 1.72
Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res (2004) 1.71
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell (2013) 1.68